X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-09-12 | CRMD | Cormedix Inc. | Todisco Joseph | CEO | S - Sale+OE | $13.00 | -50,000 | 509,496 | -9% | -$650,000 | |||||
2025-09-11 | AKRO | Akero Therapeutics, Inc. | Young Jonathan | COO | S - Sale | $43.02 | -586 | 256,898 | 0% | -$25,210 | ||||||
2025-09-11 | AKRO | Akero Therapeutics, Inc. | Yale Catriona | Chief Development Officer | S - Sale | $43.02 | -659 | 90,829 | -1% | -$28,350 | ||||||
2025-09-11 | AKRO | Akero Therapeutics, Inc. | White William Richard | CFO | S - Sale | $43.02 | -659 | 57,752 | -1% | -$28,350 | ||||||
2025-09-11 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Chief Scientific Officer | S - Sale | $43.02 | -553 | 166,571 | 0% | -$23,790 | ||||||
| DM | 2025-09-10 | AKRO | Akero Therapeutics, Inc. | Cheng Andrew | Pres, CEO | S - Sale+OE | $43.23 | -31,796 | 473,902 | -6% | -$1,374,665 | |||||
| M | 2025-09-10 | AARD | Aardvark Therapeutics, Inc. | Lee Tien-Li | CEO, 10% | P - Purchase | $8.03 | +20,000 | 3,007,412 | +1% | +$160,654 | |||||
| D | 2025-09-11 | MIRM | Mirum Pharmaceuticals, Inc. | Brege Laura | Dir | S - Sale+OE | $74.40 | -17,000 | 15,703 | -52% | -$1,264,868 | |||||
| D | 2025-09-12 | MIRM | Mirum Pharmaceuticals, Inc. | Bjerkholt Eric | CFO | S - Sale+OE | $76.01 | -9,578 | 39,945 | -19% | -$728,024 | |||||
2025-09-11 | VTRS | Viatris Inc | Le Goff Corinne | Chief Commercial Officer | S - Sale | $10.25 | -7,032 | 35,299 | -17% | -$72,045 | ||||||
| D | 2025-09-11 | CYRX | Cryoport, Inc. | Hariri Robert J | Dir | S - Sale+OE | $9.71 | -25,000 | 51,275 | -33% | -$242,738 | |||||
2025-09-11 | XERS | Xeris Biopharma Holdings, Inc. | Persky Marla | Dir | S - Sale | $7.72 | -15,500 | 148,370 | -9% | -$119,610 | ||||||
2025-09-10 | PMVP | Pmv Pharmaceuticals, Inc. | Orbimed Advisors LLC | 10% | S - Sale | $1.80 | -500,000 | 5,975,291 | -8% | -$900,000 | ||||||
2025-09-11 | TGTX | Tg Therapeutics, Inc. | Lonial Sagar | Dir | S - Sale | $32.24 | -20,852 | 94,061 | -18% | -$672,268 | ||||||
| D | 2025-09-10 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $325.53 | -10,006 | 237,562 | -4% | -$3,257,289 | |||||
2025-09-10 | ZLAB | Zai Lab Ltd | Smiley Joshua L | See Remarks | P - Purchase | $28.91 | +10,000 | 86,604 | +13% | +$289,100 | ||||||
| D | 2025-09-10 | NUVL | Nuvalent, Inc. | Pelish Henry E. | Chief Scientific Officer | S - Sale+OE | $78.83 | -3,725 | 65,963 | -5% | -$293,642 | |||||
2025-09-12 | RARE | Ultragenyx Pharmaceutical Inc. | Parschauer Karah Herdman | EVP, GC | S - Sale | $31.17 | -2,450 | 73,271 | -3% | -$76,367 | ||||||
| D | 2025-09-11 | RNA | Avidity Biosciences, Inc. | Flanagan W. Michael | Chief Scientific Officer | S - Sale+OE | $38.94 | -20,000 | 80,195 | -20% | -$778,702 | |||||
2025-09-10 | APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | GC | S - Sale | $26.17 | -20,000 | 183,866 | -10% | -$523,400 | ||||||
| M | 2025-08-01 | CPIX | Cumberland Pharmaceuticals Inc | Young Caroline | Dir | P - Purchase | $3.29 | +121 | 32,942 | 0% | +$398 | |||||
| M | 2025-08-01 | CPIX | Cumberland Pharmaceuticals Inc | Jones James | Dir | P - Purchase | $3.29 | +262 | 43,938 | +1% | +$862 | |||||
| M | 2025-08-01 | CPIX | Cumberland Pharmaceuticals Inc | Kazimi A J | COB, CEO, 10% | P - Purchase | $3.29 | +262 | 5,700,030 | 0% | +$862 | |||||
| M | 2025-08-01 | CPIX | Cumberland Pharmaceuticals Inc | Krogulski Kenneth | Dir | P - Purchase | $3.29 | +1,372 | 289,717 | 0% | +$4,516 | |||||
| D | 2025-09-09 | CRMD | Cormedix Inc. | Zelnick Kaufman Beth | GC | S - Sale+OE | $13.41 | -50,000 | 180,418 | -22% | -$670,264 | |||||
| DM | 2025-09-09 | CRMD | Cormedix Inc. | Hurlburt Elizabeth | COO | S - Sale+OE | $13.18 | -53,997 | 176,990 | -23% | -$711,817 | |||||
2025-09-09 | NKTR | Nektar Therapeutics | Robin Howard W | Pres, CEO | S - Sale | $46.69 | -6,666 | 49,370 | -12% | -$311,214 | ||||||
| M | 2025-09-09 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $40.59 | -21,120 | 55,200 | -28% | -$857,313 | |||||
| D | 2025-09-10 | CORT | Corcept Therapeutics Inc | Swisher Daniel N Jr | Dir | S - Sale+OE | $72.45 | -2,200 | 0 | -100% | -$159,390 | |||||
| M | 2025-09-09 | BYSI | Beyondspring Inc. | Decheng Capital China Life Sciences Usd Fund Iii, L.P. | 10% | S - Sale | $1.94 | -21,046 | 4,383,853 | 0% | -$40,866 | |||||
| DM | 2025-09-10 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $397.97 | -8,000 | 644,489 | -1% | -$3,183,777 | |||||
| M | 2025-09-10 | SMMT | Summit Therapeutics Inc. | Zanganeh Mahkam | Co-CEO, 10% | P - Purchase | $17.69 | +338,394 | 591,831,532 | 0% | +$5,984,756 | |||||
| M | 2025-09-10 | SMMT | Summit Therapeutics Inc. | Duggan Robert W | Co-CEO, 10% | P - Purchase | $17.69 | +338,394 | 591,831,532 | 0% | +$5,984,756 | |||||
2025-09-09 | LFVN | Lifevantage Corp | Beindorff Michael A | Dir | S - Sale | $11.44 | -4,325 | 119,897 | -3% | -$49,460 | ||||||
2025-09-11 | RAPP | Rapport Therapeutics, Inc. | Young Wendy B. | Dir | P - Purchase | $22.60 | +3,500 | 9,500 | +58% | +$79,100 | ||||||
| DM | 2025-09-09 | CNTA | Centessa Pharmaceuticals Plc | Bush Tia L | Chief Technology, Quality Ofc | S - Sale+OE | $21.00 | -49,792 | 121,503 | -29% | -$1,045,840 | |||||
| DM | 2025-09-09 | CNTA | Centessa Pharmaceuticals Plc | Hussain Iqbal J | GC | S - Sale+OE | $21.00 | -40,000 | 110,886 | -27% | -$840,102 | |||||
| D | 2025-09-09 | CNTA | Centessa Pharmaceuticals Plc | Accardi Mario Alberto | Pres, Orexin Program | S - Sale+OE | $20.00 | -7,000 | 205,566 | -3% | -$140,000 | |||||
| D | 2025-09-09 | DNTH | Dianthus Therapeutics, Inc. /De/ | Savitz Ryan | CFO, CBO | S - Sale+OE | $35.00 | -20,000 | 0 | -100% | -$700,000 | |||||
2025-09-09 | ONC | Beone Medicines Ltd. | Wang Lai | Global Head of R, D | S - Sale | $350.06 | -5,000 | 1,625,494 | 0% | -$1,750,312 | ||||||
| D | 2025-09-09 | IONS | Ionis Pharmaceuticals Inc | Baroldi Joseph | EVP, Chief Business Officer | S - Sale+OE | $62.16 | -11,950 | 34,997 | -25% | -$742,838 | |||||
| D | 2025-09-09 | IONS | Ionis Pharmaceuticals Inc | O'Neil Patrick R. | EVP CLO, GC | S - Sale+OE | $64.56 | -21,000 | 57,130 | -27% | -$1,355,661 | |||||
2025-09-11 | CAMP | Camp4 Therapeutics Corp | Polaris Management Co. Vii, L.L.C. | 10% | P - Purchase | $1.53 | +1,307,189 | 1,106,751 | -652% | +$1,999,999 | ||||||
2025-09-11 | CAMP | Camp4 Therapeutics Corp | Nashat Amir | Dir, 10% | P - Purchase | $1.53 | +1,307,189 | 1,106,751 | -652% | +$1,999,999 | ||||||
| D | 2025-09-09 | PTCT | Ptc Therapeutics, Inc. | Southwell David P | Dir | S - Sale+OE | $58.34 | -12,000 | 16,850 | -42% | -$700,080 | |||||
2025-09-11 | CAMP | Camp4 Therapeutics Corp | Maricich Yuri | Chief Medical Officer | P - Purchase | $1.65 | +6,060 | 6,060 | New | +$9,999 | ||||||
2025-09-11 | CAMP | Camp4 Therapeutics Corp | Gold Kelly | CFO | P - Purchase | $1.65 | +6,060 | 67,877 | +10% | +$9,999 | ||||||
2025-09-11 | CAMP | Camp4 Therapeutics Corp | Mandel-Brehm Josh | CEO | P - Purchase | $1.65 | +6,060 | 278,417 | +2% | +$9,999 | ||||||
2025-09-11 | CAMP | Camp4 Therapeutics Corp | Young Richard A | Dir | P - Purchase | $1.65 | +15,151 | 170,010 | +10% | +$24,999 | ||||||
| M | 2025-09-10 | BSPK | Bespoke Extracts, Inc. | Feinsod Michael | CEO, 10% | P - Purchase | $0.22 | +3,500 | 2,512,112 | 0% | +$785 | |||||
| D | 2025-09-09 | ALNY | Alnylam Pharmaceuticals, Inc. | Reitan Colleen F | Dir | S - Sale+OE | $467.60 | -18,000 | 775 | -96% | -$8,416,730 | |||||
2025-09-09 | CALC | Calcimedica, Inc. | Roberts Eric W | CHIEF BUSINESS OFFICER, 10% | P - Purchase | $3.15 | +2,343 | 1,052,837 | 0% | +$7,378 | ||||||
2025-09-08 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale | $20.24 | -6,667 | 283,308 | -2% | -$134,957 | ||||||
| D | 2025-09-08 | AKRO | Akero Therapeutics, Inc. | Rolph Timothy | Chief Scientific Officer | S - Sale+OE | $44.17 | -12,500 | 167,124 | -7% | -$552,137 | |||||
| M | 2025-09-08 | ARQT | Arcutis Biotherapeutics, Inc. | Watanabe Todd | See Remarks | S - Sale | $17.54 | -10,129 | 1,124,574 | -1% | -$177,628 | |||||
| D | 2025-09-08 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Dir | S - Sale+OE | $0.00 | -17,000 | 0 | -100% | -$0 | |||||
| D | 2025-09-09 | NAMS | Newamsterdam Pharma Co N.V. | Kooij Louise Frederika | Chief Accounting Officer | S - Sale+OE | $25.83 | -150,000 | 15,000 | -91% | -$3,874,017 | |||||
2025-09-09 | AARD | Aardvark Therapeutics, Inc. | Sun Nelson | CFO | P - Purchase | $8.07 | +6,000 | 105,484 | +6% | +$48,440 | ||||||
2025-09-08 | NAMS | Newamsterdam Pharma Co N.V. | Topper James N | Dir | P - Purchase | $24.99 | +1,260 | 6,828,864 | 0% | +$31,487 | ||||||
| D | 2025-09-08 | CPRX | Catalyst Pharmaceuticals, Inc. | Elsbernd Brian | Chief Compliance, Legal Office | S - Sale+OE | $20.30 | -30,000 | 271,039 | -10% | -$609,000 | |||||
| DM | 2025-09-08 | UTHR | United Therapeutics Corp | Benkowitz Michael | Pres, COO | S - Sale+OE | $395.82 | -16,375 | 2,648 | -86% | -$6,481,612 | |||||
2025-09-09 | UTHR | United Therapeutics Corp | Malcolm Jan | Dir | S - Sale | $400.29 | -700 | 520 | -57% | -$280,203 | ||||||
| D | 2025-09-09 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $398.55 | -8,000 | 644,489 | -1% | -$3,188,374 | |||||
| D | 2025-09-10 | UTHR | United Therapeutics Corp | Thompson Tommy G | Dir | S - Sale+OE | $403.36 | -4,560 | 22,480 | -17% | -$1,839,322 | |||||
2025-09-08 | PRGO | Perrigo Co Plc | Lennox Abigail | EVP, CSO | P - Purchase | $22.41 | +1,255 | 1,255 | New | +$28,125 | ||||||
| D | 2025-09-08 | RAPP | Rapport Therapeutics, Inc. | Gault Cheryl | COO | S - Sale+OE | $38.33 | -5,000 | 171,928 | -3% | -$191,650 | |||||
| D | 2025-09-09 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale+OE | $51.29 | -2,000 | 140,610 | -1% | -$102,580 | |||||
| D | 2025-09-08 | APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | CFO | S - Sale+OE | $27.85 | -42,729 | 171,332 | -20% | -$1,190,130 | |||||
2025-09-05 | CYCC | Cyclacel Pharmaceuticals, Inc. | Kua Khai Loon | 10% | S - Sale | $7.01 | -19,054 | 385,411 | -5% | -$133,569 | ||||||
2025-09-09 | MDGL | Madrigal Pharmaceuticals, Inc. | Sibold William John | Pres, CEO | S - Sale | $445.63 | -7,279 | 102,474 | -7% | -$3,243,741 | ||||||
2025-09-08 | AXSM | Axsome Therapeutics, Inc. | Coleman Mark | Dir | P - Purchase | $127.28 | +1,575 | 452,068 | 0% | +$200,466 | ||||||
| D | 2025-09-08 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $15.84 | -7,294 | 395,189 | -2% | -$115,537 | |||||
| D | 2025-09-08 | URGN | Urogen Pharma Ltd. | Schoenberg Mark | Chief Medical Officer | S - Sale+OE | $19.11 | -871 | 149,025 | -1% | -$16,645 | |||||
| D | 2025-09-08 | URGN | Urogen Pharma Ltd. | Smith Jason Drew | GC | S - Sale+OE | $19.11 | -1,520 | 43,305 | -3% | -$29,047 | |||||
| D | 2025-09-05 | IONS | Ionis Pharmaceuticals Inc | Baroldi Joseph | EVP, Chief Business Officer | S - Sale+OE | $62.00 | -250 | 34,997 | -1% | -$15,500 | |||||
2025-09-05 | IONS | Ionis Pharmaceuticals Inc | Bennett C Frank | EVP, Chief Scientific Officer | S - Sale | $59.60 | -6,000 | 82,679 | -7% | -$357,581 | ||||||
| D | 2025-09-05 | RNA | Avidity Biosciences, Inc. | Wilson Troy Edward | Dir | S - Sale+OE | $50.00 | -29,500 | 68,136 | -30% | -$1,475,000 | |||||
| D | 2025-09-05 | ONC | Beone Medicines Ltd. | Sanders Corazon (Corsee) D. | Dir | S - Sale+OE | $337.00 | -2,665 | 57,226 | -4% | -$898,105 | |||||
| D | 2025-09-08 | PTCT | Ptc Therapeutics, Inc. | Pauwels Eric | CHIEF BUSINESS OFFICER | S - Sale+OE | $56.92 | -39,850 | 72,912 | -35% | -$2,268,374 | |||||
2025-09-05 | PHAT | Phathom Pharmaceuticals, Inc. | Breedlove Robert Charles | Principal Accounting Officer | S - Sale | $12.09 | -461 | 54,876 | -1% | -$5,573 | ||||||
2025-09-05 | DYN | Dyne Therapeutics, Inc. | Cox John | CEO, Pres | S - Sale | $13.41 | -2,640 | 271,539 | -1% | -$35,402 | ||||||
2025-09-08 | KURA | Kura Oncology, Inc. | Wilson Troy Edward | Pres, CEO | P - Purchase | $8.20 | +50,000 | 680,162 | +8% | +$410,145 | ||||||
2025-09-05 | AGIO | Agios Pharmaceuticals, Inc. | Washburn Theodore James Jr. | Principal Accounting Officer | S - Sale | $36.87 | -8,546 | 868 | -91% | -$315,091 | ||||||
| D | 2025-09-08 | SUPN | Supernus Pharmaceuticals, Inc. | Khattar Jack A. | Pres, CEO | S - Sale+OE | $46.29 | -6,322 | 1,111,983 | -1% | -$292,645 | |||||
| M | 2025-09-05 | TNGX | Tango Therapeutics, Inc. | Third Rock Ventures Iv, L.P. | 10% | S - Sale | $7.00 | -729,365 | 14,727,516 | -5% | -$5,108,970 | |||||
2025-09-05 | TEVA | Teva Pharmaceutical Industries Ltd | McAvoy David R. | EVP, GC | P - Purchase | $18.86 | +1,113 | 13,027 | +9% | +$20,988 | ||||||
2025-09-05 | PRGO | Perrigo Co Plc | Atkinson Charles | EVP, GC, Sec. | P - Purchase | $23.20 | +1,000 | 1,000 | New | +$23,200 | ||||||
2025-09-04 | NKTR | Nektar Therapeutics | Zalevsky Jonathan | Chief R, D Officer | S - Sale | $33.52 | -1,721 | 17,462 | -9% | -$57,693 | ||||||
| M | 2025-09-04 | NKTR | Nektar Therapeutics | Robin Howard W | Pres, CEO | S - Sale | $36.42 | -11,832 | 56,036 | -17% | -$430,959 | |||||
2025-09-04 | MLYS | Mineralys Therapeutics, Inc. | Akkaraju Srinivas | Dir | P - Purchase | $25.50 | +588,235 | 6,263,151 | +10% | +$14,999,993 | ||||||
2025-09-08 | BSPK | Bespoke Extracts, Inc. | Feinsod Michael | CEO, 10% | P - Purchase | $0.19 | +2,500 | 2,508,612 | 0% | +$475 | ||||||
| D | 2025-09-04 | AQST | Aquestive Therapeutics, Inc. | Jung Cassie | COO | S - Sale+OE | $5.00 | -62,180 | 285,346 | -18% | -$310,900 | |||||
| M | 2025-09-04 | BYSI | Beyondspring Inc. | Decheng Capital China Life Sciences Usd Fund Iii, L.P. | 10% | S - Sale | $1.91 | -8,999 | 4,404,899 | 0% | -$17,202 | |||||
| D | 2025-09-08 | SNDX | Syndax Pharmaceuticals Inc | Metzger Michael A | CEO | S - Sale+OE | $16.41 | -157,307 | 298,661 | -34% | -$2,582,021 | |||||
| D | 2025-09-05 | BBIO | Bridgebio Pharma, Inc. | McCormick Frank | Dir | S - Sale+OE | $53.16 | -74,000 | 963,254 | -7% | -$3,933,544 | |||||
| M | 2025-09-04 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $52.20 | -80,000 | 5,777,223 | -1% | -$4,175,835 | |||||
2025-09-04 | MLYS | Mineralys Therapeutics, Inc. | Ra Capital Management, L.P. | Dir | P - Purchase | $25.50 | +1,176,470 | 7,323,750 | +19% | +$29,999,985 | ||||||
2025-09-04 | PCRX | Pacira Biosciences, Inc. | Ceesay Abraham | Dir | S - Sale | $27.19 | -2,354 | 9,039 | -21% | -$64,005 | ||||||
2025-09-04 | ARQT | Arcutis Biotherapeutics, Inc. | Matsuda Masaru | See Remarks | S - Sale | $16.16 | -36,130 | 161,234 | -18% | -$583,716 | ||||||
2025-09-05 | AQST | Aquestive Therapeutics, Inc. | Boyd Peter E. | See Remarks | S - Sale | $5.30 | -15,000 | 288,323 | -5% | -$79,500 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |